BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 37108713)

  • 1. In Silico Design of a Chimeric Humanized L-asparaginase.
    Pedroso A; Herrera Belén L; Beltrán JF; Castillo RL; Pessoa A; Pedroso E; Farías JG
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
    Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
    Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme Engineering Strategies for the Bioenhancement of L-Asparaginase Used as a Biopharmaceutical.
    Miranda J; Lefin N; Beltran JF; Belén LH; Tsipa A; Farias JG; Zamorano M
    BioDrugs; 2023 Nov; 37(6):793-811. PubMed ID: 37698749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
    Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora.
    Belén LH; Lissabet JB; de Oliveira Rangel-Yagui C; Effer B; Monteiro G; Pessoa A; Farías Avendaño JG
    Biologicals; 2019 May; 59():47-55. PubMed ID: 30871932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality comparison of a state-of-the-art preparation of a recombinant L-asparaginase derived from Escherichia coli with an alternative asparaginase product.
    Schnuchel A; Radcke C; Theobald L; Doeding S
    PLoS One; 2023; 18(6):e0285948. PubMed ID: 37319282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
    Ghasemian A; Al-Marzoqi AH; Al-Abodi HR; Alghanimi YK; Kadhum SA; Shokouhi Mostafavi SK; Fattahi A
    J Cell Physiol; 2019 Nov; 234(11):19271-19279. PubMed ID: 30993718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.
    Huerta-Saquero A; Evangelista-Martínez Z; Moreno-Enriquez A; Perez-Rueda E
    Bioengineered; 2013; 4(1):30-6. PubMed ID: 22895060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.
    Albertsen BK; Schrøder H; Ingerslev J; Jakobsen P; Avramis VI; Müller HJ; Carlsen NT; Schmiegelow K
    Br J Haematol; 2001 Dec; 115(4):983-90. PubMed ID: 11843837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-asparaginase production review: bioprocess design and biochemical characteristics.
    Castro D; Marques ASC; Almeida MR; de Paiva GB; Bento HBS; Pedrolli DB; Freire MG; Tavares APM; Santos-Ebinuma VC
    Appl Microbiol Biotechnol; 2021 Jun; 105(11):4515-4534. PubMed ID: 34059941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F).
    Ardalan N; Akhavan Sepahi A; Khavari-Nejad RA
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1137-1147. PubMed ID: 33906306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
    Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
    Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
    Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase.
    Patel N; Krishnan S; Offman MN; Krol M; Moss CX; Leighton C; van Delft FW; Holland M; Liu J; Alexander S; Dempsey C; Ariffin H; Essink M; Eden TO; Watts C; Bates PA; Saha V
    J Clin Invest; 2009 Jul; 119(7):1964-73. PubMed ID: 19509471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyoxazoline-Conjugated l-Asparaginase: An Antibody-Production-Free Therapeutic Agent for Acute Lymphoblastic Leukemia.
    Yamada T; Ishimaru M; Shoji T; Tomiyasu H; Tochinai R; Taguchi K; Komatsu T
    ACS Appl Bio Mater; 2023 Dec; 6(12):5789-5797. PubMed ID: 38047730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.
    van der Sluis IM; de Groot-Kruseman H; Te Loo M; Tissing WJE; van den Bos C; Kaspers GJL; Bierings M; Kollen WJW; König T; Pichlmeier U; Kühnel HJ; Pieters R
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27083. PubMed ID: 29727043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circumventing the side effects of L-asparaginase.
    Fonseca MHG; Fiúza TDS; Morais SB; Souza TACB; Trevizani R
    Biomed Pharmacother; 2021 Jul; 139():111616. PubMed ID: 33932739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-asparaginase from
    Saeed H; Elsawy E; Shalaby M; Abdel-Fattah M; Hemida A; Eldoksh A; Ataya FS; Nematalla H; Elkewedi M; Labrou NN; El-Nikhely N
    Prep Biochem Biotechnol; 2022; 52(6):668-680. PubMed ID: 34612174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards development of biobetter: L-asparaginase a case study.
    Tripathy RK; Anakha J; Pande AH
    Biochim Biophys Acta Gen Subj; 2024 Jan; 1868(1):130499. PubMed ID: 37914146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.